Foundayo is Eli Lilly's brand name for orforglipron, a small-molecule, non-peptide GLP-1 receptor agonist that the FDA approved on April 1, 2026, under its national priority voucher program for adults with obesity or with overweight plus a weight-related medical condition. Unlike Wegovy, Ozempic, Zepbound, and Mounjaro, which are injected peptides, Foundayo is the first once-daily GLP-1 pill that can be taken any time of day without food or water restrictions, since orforglipron does not require the fasting window that the oral Wegovy tablet needs to absorb properly. Lilly began shipping Foundayo through its LillyDirect pharmacy on April 6, 2026, followed by broader availability at retail pharmacies including Walmart, Walgreens, and CVS within weeks of approval. Analysts project Foundayo could reach several million prescriptions in its first full year on the market given the demand already seen for injectable GLP-1 drugs.
Eli Lilly set Foundayo's wholesale list price at roughly $649 per month, though the average cash price patients see at a retail pharmacy counter runs closer to $649 to $782 per month depending on dose and location in 2026. Because Foundayo launched only months ago, cash pricing at individual pharmacy chains is still settling, and patients should expect variation by ZIP code. What a given patient actually pays depends heavily on which channel they use: full retail cash, the LillyDirect self-pay program, a commercial savings card, or Medicare's temporary GLP-1 Bridge, which are each covered in the tables below. Patients comparing GLP-1 options for weight management should also review Zepbound and Wegovy cost pages, since coverage rules differ across all three drugs.
Medicare beneficiaries face a specific timing issue with Foundayo. Standard Medicare Part D does not cover any GLP-1 drug prescribed solely for weight loss, a restriction written into the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. CMS created the Medicare GLP-1 Bridge, a temporary demonstration program described at cms.gov, to work around that restriction starting July 1, 2026, covering Foundayo, Wegovy, and the Zepbound KwikPen for a flat $50 monthly copay. Between Foundayo's April 2026 launch and the Bridge's July 2026 start date, Medicare beneficiaries had no standard coverage pathway and relied on LillyDirect self-pay or the commercial savings card if they had other coverage. See the Medicare GLP-1 Bridge program page for full eligibility rules.
What Foundayo Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same foundayo can cost many times more at a hospital than at your local pharmacy:
2026 Foundayo Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Pharmacy counter (retail, cash, no coupon) | $649 - $782/month | 2026 list-adjacent cash price without insurance or manufacturer discount; varies by dose and pharmacy. |
| Medicare GLP-1 Bridge (from July 1, 2026) | $50/month flat copay | Requires one of three BMI pathways. Does not count toward the $2,100 Part D annual out-of-pocket cap. Not covered under standard Part D before July 2026. |
| Commercial insurance with Foundayo Savings Card | $25/month (Lilly covers up to $100/month of copay) | Requires commercial insurance that covers Foundayo, prior authorization, and no Medicare, Medicaid, TRICARE, or VA benefits. |
| LillyDirect self-pay (no insurance) | $149 - $299/month depending on dose | No income requirement, no insurance required. Cannot be combined with insurance or the savings card. |
| Medicaid (state-dependent) | $1 - $4/prescription in participating states | Covered with prior authorization in roughly 13 states participating in the Medicaid BALANCE model as of 2026; not covered in most other states. |
Retail prices reflect 2026 GoodRx and pharmacy survey data collected shortly after Foundayo's April 2026 launch; expect continued price movement as more pharmacies stock the drug. Bridge and Medicaid figures come from CMS program documentation.
Source: CMS Medicare GLP-1 Bridge program documentation, LillyDirect, GoodRx, FDA approval label
Why Hospitals Charge So Much
Foundayo is a self-administered oral tablet and is rarely dispensed in a hospital setting, since patients take it at home once daily rather than receiving it as part of an inpatient treatment protocol. When Foundayo does appear on an inpatient itemized bill, usually because a patient brought their own supply or a hospital pharmacy dispensed a short course during an admission, the charge can run several times the retail cash price. Hospital pharmacies apply facility-rate markups on top of acquisition cost, covering pharmacy handling, nursing administration, and general overhead, the same pattern seen across brand-name GLP-1 drugs like Ozempic and Zepbound. Because Foundayo only launched in April 2026, few hospital billing systems have established a standardized charge for it yet, which increases the odds of an inconsistent or inflated line item on an itemized bill.
Patients who see Foundayo billed at $1,500 or more for a 30-day supply on a hospital itemized bill should request the line-item cost and the National Drug Code (NDC). The 2026 wholesale price for a month of Foundayo is roughly $649, so any inpatient charge substantially above that reflects a facility markup rather than the drug's actual cost. Most commercial insurance and Medicare will only reimburse the outpatient pharmacy rate for a self-administered oral drug like Foundayo, leaving any inpatient markup exposed to dispute or negotiation by the patient. Ask the hospital billing office for an itemized statement and compare the Foundayo line item against the LillyDirect self-pay price of $149 to $299 per month before agreeing to pay, since the gap between those two figures is often the clearest evidence for a successful bill dispute.
Patient Assistance Programs
Foundayo does not have a traditional income-based patient assistance program (PAP) the way older brand drugs do. Lilly Cares Foundation, Eli Lilly's charitable PAP that covers Mounjaro for type 2 diabetes, does not currently cover Foundayo. Instead, Eli Lilly offers two launch-year affordability channels: LillyDirect self-pay for uninsured patients and a commercial savings card for insured patients. Neither program requires proof of income or an FPL-based eligibility calculation.
Patient assistance programs for Foundayo| Manufacturer program | Cost / Benefit | How to apply |
|---|
| LillyDirect Self-Pay Journey Program | $149/month (0.8mg-2.5mg), $199/month (5.5mg), $299/month (9mg-17.2mg); no income requirement; cannot combine with insurance | lilly.com/lillydirect/medicines/foundayo |
| Foundayo Savings Card (commercially insured only) | As low as $25/month copay for commercially-insured patients; Lilly covers up to $100/month; not valid with Medicare, Medicaid, TRICARE, or VA | foundayo.com/savings |
| Medicare GLP-1 Bridge (effective July 1, 2026) | $50/month flat copay for Medicare Part D enrollees who meet one of three BMI pathways | medicare.gov/coverage/weight-loss-drugs |
| NeedyMeds Drug Discount Card | Variable discount, generally modest, accepted at most US pharmacies | needymeds.org |
Manufacturer copay savings cards, including the Foundayo Savings Card, are not available to Medicare, Medicaid, TRICARE, or VA beneficiaries by federal anti-kickback law (42 U.S.C. § 1320a-7b). A manufacturer coupon like the Foundayo Savings Card only works with commercial insurance. Medicare enrollees should ask about the Medicare GLP-1 Bridge instead. Because Lilly Cares Foundation does not cover Foundayo as of 2026, uninsured patients without Bridge or Medicaid eligibility should default to the LillyDirect self-pay price.
Source: LillyDirect Foundayo self-pay terms, Foundayo Savings Card terms, CMS Medicare GLP-1 Bridge documentation, NeedyMeds.org
Medicare Part D
Standard Medicare Part D does not cover Foundayo because federal law bars Part D plans from covering any drug used solely for weight loss, a rule dating to the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. That statutory exclusion applies to Foundayo the same way it applies to Wegovy and the Zepbound KwikPen. Medicare beneficiaries who need Foundayo for an FDA-approved obesity or overweight-with-comorbidity indication have no coverage under the ordinary Part D formulary tier structure, and no formulary tier placement or prior authorization approval can override that statutory exclusion outside of the Bridge demonstration described below. The distinction matters because patients frequently assume that once a drug clears FDA approval, standard Medicare automatically covers it, which is not the case for weight-loss-labeled GLP-1 drugs.
CMS launched the Medicare GLP-1 Bridge on July 1, 2026, as a Section 402 demonstration program that runs outside the standard Part D benefit through December 31, 2027. Eligible Medicare Part D enrollees pay a flat $50 monthly copay for Foundayo, Wegovy, or the Zepbound KwikPen if they meet one of three BMI pathways: a BMI of 35 or higher alone, a BMI of 30 or higher with heart failure, uncontrolled hypertension, or chronic kidney disease, or a BMI of 27 or higher with pre-diabetes, a prior heart attack, stroke, or peripheral artery disease. The $50 copay does not count toward the standard $2,100 annual Part D out-of-pocket cap for 2026, and Extra Help (LIS) cost-sharing assistance does not apply to it.
Medicare beneficiaries who do not qualify for the Bridge, or who need Foundayo before their plan finishes loading the program, continue to face the full retail or LillyDirect self-pay price. CMS originally planned a permanent replacement called the BALANCE Model starting in 2027, but shelved it on April 21, 2026, citing insufficient Part D plan sponsor participation, and extended the Bridge through the end of 2027 instead. What happens to Foundayo's Medicare coverage after December 31, 2027 remains unresolved as of this writing.
Common Foundayo Billing Errors
If you were charged more than $299/month for Foundayo through LillyDirect, more than $50/month through the Medicare GLP-1 Bridge, or the full $649-$782 retail price despite having a savings card, check for these launch-year billing issues before paying:
- Pharmacy billed the full cash price instead of applying the Foundayo Savings Card BIN/PCN. Because Foundayo just launched, some pharmacy systems have not yet loaded the card correctly; ask the pharmacist to rerun the claim.
- Medicare Part D plan has not yet loaded the GLP-1 Bridge NDC codes, causing a claim to reject or price at full retail instead of the $50 flat copay. Ask your plan to confirm Bridge enrollment before your next fill.
- Wrong dose tier billed: the 0.8mg starter dose billed at the higher 9mg-17.2mg maintenance-dose price. Confirm the National Drug Code on your receipt matches your prescribed dose.
- The $50 Medicare GLP-1 Bridge copay incorrectly applied toward the $2,100 annual Part D out-of-pocket cap. Per CMS rules, Bridge copays sit outside standard Part D accounting and should not appear on your Explanation of Benefits as counting toward the cap.
- LillyDirect self-pay order billed twice: once to the LillyDirect pharmacy directly and again submitted through commercial insurance, which is not permitted since the two channels cannot be combined.
- Medicaid claim submitted in a state that is not among the roughly 13 states participating in the Medicaid BALANCE model, resulting in an automatic denial rather than the expected $1-$4 copay.
Frequently Asked Questions
Is there a generic version of Foundayo (orforglipron)?
No. Foundayo, approved by the FDA in April 2026, has no generic or biosimilar equivalent. Eli Lilly's composition-of-matter patent on orforglipron is expected to run through approximately 2036, with broader brand exclusivity likely extending into the late 2030s. Because orforglipron is a small molecule rather than a biologic, any future competition would arrive as a generic through the standard ANDA pathway rather than as a biosimilar. Foundayo is currently the only FDA-approved once-daily oral GLP-1 pill for weight management.
How do I apply for cost assistance if I don't have insurance for Foundayo?
Foundayo does not have a traditional income-based patient assistance program; Lilly Cares Foundation does not currently cover it. Uninsured patients should instead enroll in the LillyDirect Self-Pay Journey Program at lilly.com/lillydirect/medicines/foundayo, which prices Foundayo at $149 to $299 per month by dose with no income requirement and direct home shipping. Commercially insured patients should use the Foundayo Savings Card instead, which can lower a copay to as little as $25 a month.
Can I use the Foundayo savings card with Medicare?
No. Federal anti-kickback law (42 U.S.C. § 1320a-7b) bars manufacturer copay savings cards, including the Foundayo Savings Card, for anyone enrolled in Medicare, Medicaid, TRICARE, or VA benefits. Medicare beneficiaries should instead ask whether their Part D plan participates in the Medicare GLP-1 Bridge, a CMS demonstration covering Foundayo for a flat $50 monthly copay starting July 1, 2026, for patients who meet one of three BMI-based eligibility pathways.
What if my insurance denies coverage for Foundayo?
Request the written denial notice, note the specific reason cited, and file a formal appeal with a letter of medical necessity from your prescriber documenting BMI and comorbidities. If a plan requires step therapy with an injectable GLP-1 like Wegovy or Zepbound first, your prescriber can request an override citing needle phobia or intolerance. If appeals fail, LillyDirect self-pay ($149-$299/month) remains available regardless of your insurance decision.
Does the IRA's Medicare drug price negotiation apply to Foundayo?
No, not yet. Foundayo was only approved by the FDA in April 2026. Under the Inflation Reduction Act of 2022, small-molecule drugs like orforglipron become eligible for Medicare price negotiation nine years after FDA approval, so Foundayo could not receive a negotiated Maximum Fair Price before roughly 2035. In the meantime, Medicare beneficiaries rely on the temporary $50 GLP-1 Bridge copay rather than IRA negotiation, and other Part D drugs remain subject to the general $2,100 annual out-of-pocket cap for 2026.
What does Foundayo cost without insurance at the pharmacy counter in 2026?
Retail cash price at major pharmacy chains like Walmart and Walgreens runs $649 to $782 per month in 2026 depending on dose, with no coupon applied. That price is meaningfully higher than Eli Lilly's own LillyDirect Self-Pay Journey Program, which prices the same drug at $149 to $299 per month for uninsured patients with no income verification, making LillyDirect the better option for most cash-paying patients.
Do I qualify for a lower Foundayo cost?
Eligibility depends on your coverage type, not income. Commercially insured patients can use the Foundayo Savings Card for a $25 monthly copay if their plan covers the drug. Medicare Part D enrollees qualify for the $50 monthly GLP-1 Bridge copay if they have a BMI of 35 or higher alone, 30 or higher with certain heart or kidney conditions, or 27 or higher with pre-diabetes or a prior cardiovascular event. Uninsured patients qualify for LillyDirect self-pay regardless of income.
How is Foundayo different from Wegovy, Zepbound, and Ozempic?
Foundayo (orforglipron) is the first FDA-approved once-daily oral GLP-1 pill that can be taken any time of day without food or water restrictions, unlike the oral Wegovy tablet, which requires fasting. Zepbound and Ozempic are injectable weekly pens; Zepbound (tirzepatide) targets weight management and Ozempic (semaglutide) is FDA-approved for type 2 diabetes. All four drugs affect the GLP-1 pathway, but coverage rules, dosing, and cost differ significantly across them.
